<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3389">
  <stage>Registered</stage>
  <submitdate>5/12/2011</submitdate>
  <approvaldate>5/12/2011</approvaldate>
  <nctid>NCT01487161</nctid>
  <trial_identification>
    <studytitle>Study of FX006 in Patients With Osteoarthritis of the Knee</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FX006-2011-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - FX006
Treatment: drugs - Commercially available triamcinolone acetonide

Experimental: FX006 10 mg - 

Experimental: FX006 40 mg - 

Experimental: FX006 60 mg - 

Active Comparator: commercially available triamcinolone acetonide (40 mg) - 


Treatment: drugs: FX006
Single intra-articular injection

Treatment: drugs: Commercially available triamcinolone acetonide
Single intra-articular injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline to each of Weeks 8, 10 and 12 in weekly mean of the average daily (24-hour) pain intensity score.</outcome>
      <timepoint>at 8, 10 and 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of treatment emergent adverse events</outcome>
      <timepoint>through 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to each of Weeks 1, 2, 3, 4, 5, 6, 7, 9 and 11 in weekly mean of the average (24-hour) pain intensity score.</outcome>
      <timepoint>weekly through 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of onset of pain relief</outcome>
      <timepoint>weekly through 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Continuous responder at each study week</outcome>
      <timepoint>weekly through 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC A (pain subscale) change from Baseline</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC B (stiffness subscale) change from Baseline</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC C (function subscale) change from Baseline</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC (total) change from Baseline</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of responders (defined as patients with high improvement in pain or function) according to OMERACT-OARSI criteria</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in patient's and clinical observer's global impression of change scores</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average weekly and total consumption of rescue medications</outcome>
      <timepoint>weekly through 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile</outcome>
      <timepoint>through 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC A1 (pain on walking question) change from Baseline</outcome>
      <timepoint>at 1, 2, 4, 8 and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female &gt;=40 years of age

          -  Diagnosis of unilateral or bilateral OA of the knee for at least 6 months prior to
             Screening with confirmation of OA according to American College of Rheumatology
             Criteria for Classification of Idiopathic OA of the Knee (clinical and radiological)
             based on an X-ray performed within 6 months prior to Screening or during the Screening
             period

          -  Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)

          -  Body mass index (BMI) = 40 kg/m2

          -  Willingness to abstain from use of restricted medications

        Main</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Ipsilateral hip OA

          -  Fibromyalgia, chronic pain syndrome or other concurrent medical or arthritic
             conditions which could interfere with the evaluation of the index knee

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
             amyloidosis

          -  History of arthritides due to crystals (e.g., gout, pseudogout)

          -  History of infection in the index joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint (such as a torn anterior cruciate ligament)

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Oral, inhaled and intranasal corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  Active or history of malignancy within the last 5 years, with the exception of
             resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected
             cervical atypia or carcinoma in situ

          -  Insulin-dependent diabetes

          -  Active psychiatric disorder including psychosis and major depressive disorder

          -  History of or active Cushing's syndrome

          -  Any other clinically significant acute or chronic medical conditions (e.g.,
             uncontrolled diabetes)

          -  Skin breakdown at the knee where the injection would take place

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>229</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital> - Broadmeadow</hospital>
    <hospital> - Kogarah</hospital>
    <hospital> - St. Leonards</hospital>
    <hospital> - Wollongong</hospital>
    <hospital> - Kippa-Ring</hospital>
    <hospital> - Maroochyndore</hospital>
    <hospital> - Sherwood</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Malvern East</hospital>
    <postcode> - Broadmeadow</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - St. Leonards</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Kippa-Ring</postcode>
    <postcode> - Maroochyndore</postcode>
    <postcode> - Sherwood</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Malvern East</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Flexion Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of FX006 in
      patients with osteoarthritis of the knee.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01487161</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Neil Bodick, MD, PhD</name>
      <address>Flexion Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>